GLP-1 Weight Loss Programme (Wegovy / Mounjaro)

FeM Surgery's GLP-1 weight loss programme uses HSA-approved semaglutide (Wegovy) or tirzepatide (Mounjaro) under specialist medical supervision, delivering clinically proven 10–20% body weight reduction over 6–18 months with ongoing dose titration and lifestyle support.

FeM Surgery offers medically supervised GLP-1 receptor agonist therapy — the most clinically effective non-surgical weight loss treatment currently available. The programme centres on two HSA-approved medications: semaglutide (Wegovy), a once-weekly injection shown in landmark trials to reduce body weight by an average of 15%, and tirzepatide (Mounjaro), a dual GLP-1 and GIP receptor agonist that has demonstrated up to 22% mean body weight reduction in clinical studies. GLP-1 receptor agonists work by mimicking the action of naturally occurring gut hormones that regulate appetite and blood glucose. They slow gastric emptying, reduce hunger signals in the brain, and improve insulin sensitivity — resulting in reduced caloric intake and meaningful weight loss without requiring surgical intervention. The programme at FeM Surgery begins with a thorough clinical consultation to confirm patient suitability for GLP-1 therapy. Contraindications are carefully screened, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, and severe gastrointestinal disease. Baseline blood tests are completed to establish metabolic status before therapy begins. Medication is started at the lowest recommended dose and titrated upward according to a structured schedule to minimise side effects — most commonly mild nausea, which tends to diminish as the body adapts. Follow-up appointments are scheduled at regular intervals to monitor weight, assess tolerability, review blood markers, and adjust dosing as needed. The surgical and specialist context of FeM Surgery adds a significant clinical advantage: patients undergoing GLP-1 therapy who have obesity-related comorbidities — such as type 2 diabetes, non-alcoholic fatty liver disease, obstructive sleep apnoea, or polycystic ovarian syndrome — receive coordinated care across the relevant sub-specialty teams within the same practice. Treatment duration is typically 6–18 months, with most patients achieving 10–20% total body weight loss when combining GLP-1 medication with the lifestyle modification support provided throughout the programme. The clinic provides lifestyle guidance covering dietary patterns, meal timing, and physical activity to maximise and sustain results beyond the active treatment phase.